Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X.

Hum Vaccin. 2011 Jul;7(7):749-56. doi: 10.4161/hv.7.7.15573. Epub 2011 Jul 1.

2.

Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.

BMC Health Serv Res. 2013 Sep 26;13:359. doi: 10.1186/1472-6963-13-359.

3.

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Pellissier JM, Brisson M, Levin MJ.

Vaccine. 2007 Nov 28;25(49):8326-37. Epub 2007 Oct 17.

PMID:
17980938
4.

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

Hum Vaccin. 2008 May-Jun;4(3):238-45. Epub 2010 May 25.

PMID:
18382137
5.

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.

Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N.

Hum Vaccin Immunother. 2015;11(4):884-96. doi: 10.1080/21645515.2015.1011561.

6.

Cost effectiveness of herpes zoster vaccine in Canada.

Najafzadeh M, Marra CA, Galanis E, Patrick DM.

Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.

PMID:
19908924
7.

The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.

Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M.

J Med Econ. 2016 Jun;19(6):576-86. doi: 10.3111/13696998.2016.1146726. Epub 2016 Mar 2.

PMID:
26808422
8.

Cost-effectiveness of vaccination against herpes zoster.

de Boer PT, Wilschut JC, Postma MJ.

Hum Vaccin Immunother. 2014;10(7):2048-61. doi: 10.4161/hv.28670. Review.

9.

Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.

Annemans L, Bresse X, Gobbo C, Papageorgiou M.

J Med Econ. 2010;13(3):537-51. doi: 10.3111/13696998.2010.502854.

PMID:
20707768
10.

A systematic review of the cost effectiveness of herpes zoster vaccination.

Szucs TD, Pfeil AM.

Pharmacoeconomics. 2013 Feb;31(2):125-36. doi: 10.1007/s40273-012-0020-7. Review.

PMID:
23335045
11.

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):393-406. doi: 10.1586/erp.13.19. Epub 2013 Mar 28.

PMID:
23537397
12.

COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.

Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A.

Int J Technol Assess Health Care. 2016 Jan;32(4):233-240. Epub 2016 Sep 14.

PMID:
27624398
13.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Rothberg MB, Virapongse A, Smith KJ.

Clin Infect Dis. 2007 May 15;44(10):1280-8. Epub 2007 Apr 3.

PMID:
17443464
14.

Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.

Le P, Rothberg MB.

Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.

PMID:
26344036
15.

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ.

Vaccine. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8.

PMID:
23306360
16.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Hornberger J, Robertus K.

Ann Intern Med. 2006 Sep 5;145(5):317-25.

PMID:
16954357
17.

A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

Moore L, Remy V, Martin M, Beillat M, McGuire A.

Cost Eff Resour Alloc. 2010 Apr 30;8:7. doi: 10.1186/1478-7547-8-7.

18.

Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.

Tseng HF, Lewin B, Hales CM, Sy LS, Harpaz R, Bialek S, Luo Y, Jacobsen SJ, Reddy K, Huang PY, Zhang J, Anand S, Bauer EM, Chang J, Tartof SY.

J Infect Dis. 2015 Oct 15;212(8):1222-31. doi: 10.1093/infdis/jiv244. Epub 2015 Jun 1.

19.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
20.

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.

Sanford M, Keating GM.

Drugs Aging. 2010 Feb 1;27(2):159-76. doi: 10.2165/10489140-000000000-00000. Review.

PMID:
20104941

Supplemental Content

Support Center